JP2017515840A5 - - Google Patents

Info

Publication number

JP2017515840A5

JP2017515840A5 JP2016567399A JP2016567399A JP2017515840A5 JP 2017515840 A5 JP2017515840 A5 JP 2017515840A5 JP 2016567399 A JP2016567399 A JP 2016567399A JP 2016567399 A JP2016567399 A JP 2016567399A JP 2017515840 A5 JP2017515840 A5 JP 2017515840A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

combination

pharmaceutically acceptable

composition according

compound

Prior art date

2015-05-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 16
• 239000008194 pharmaceutical composition Substances 0.000 claims 14
• 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 9
• 239000002911 sialidase inhibitor Substances 0.000 claims 9
• 150000003839 salts Chemical class 0.000 claims 7
• NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 claims 6
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 6
• VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 6
• 229960003752 oseltamivir Drugs 0.000 claims 6
• 229960001028 zanamivir Drugs 0.000 claims 6
• ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 6
• 239000003814 drug Substances 0.000 claims 5
• 238000004519 manufacturing process Methods 0.000 claims 5
• 208000035473 Communicable disease Diseases 0.000 claims 4
• 206010057190 Respiratory tract infections Diseases 0.000 claims 4
• 208000015181 infectious disease Diseases 0.000 claims 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims 4
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
• ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 3
• 229950008454 favipiravir Drugs 0.000 claims 3
• 229960000329 ribavirin Drugs 0.000 claims 3
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
• 239000002253 acid Substances 0.000 claims 2
• 239000007864 aqueous solution Substances 0.000 claims 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
• 229960004853 betadex Drugs 0.000 claims 2
• 229910000042 hydrogen bromide Inorganic materials 0.000 claims 2
• 206010022000 influenza Diseases 0.000 claims 2
• 238000001990 intravenous administration Methods 0.000 claims 2
• NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
• 229920000858 Cyclodextrin Polymers 0.000 claims 1
• 239000002552 dosage form Substances 0.000 claims 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1